Mode of Action
POLIVY is a first-in-class CD79b-directed antibody-drug conjugate (ADC)1
POLIVY is engineered for targeted activity against dividing B cells1
ADC internalization
Once bound to CD79B, POLIVY and the receptor are internailized within the B cell
Cytotoxin delivery
The stable linker is then cleaved, releasing MMAE within the B cell
Microtubule disruption and apoptosis induction
MMAE binds to microtubules and kills dividing cells by inhibiting cell division and including apoptosis
Apoptosis
Apoptosis of dividing B cells, including malignant cells, occurs.
M-IL-00002276
POLIVY + R-CHP modifies a standard regimen by replacing vincristine, an early-generation microtubule inhibitor, with POLIVY, a CD79b-targeted, microtubule-disrupting ADC1,2
CD = cluster of differentiation; MMAE = monomethyl auristatin E.
Contact The Hematology Team
Roche Pharmaceuticals (Israel) Ltd.
🏢 6 Hacharash St. Hod Hasharon
📞09-9737777
📧 israel.Hematology@roche.com
References:
- POLIVY, Israeli MoH approved prescribing information,Aug 2022
- Fanale D, Bronte G, Passiglia F, et al. Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? Anal Cell Pathol. 2015;690916